<p>Strs Ohio 在最近向證券交易委員會提交的 13F 文件中表示，在第四季度將其在 ResMed Inc.（紐約證券交易所代碼：RMD - 免費報告）的持股削減了 89.7%。該公司在此期間出售了 30,494 股後，持有 3,497 股該醫療設備提供商的股票。Strs Ohio 在 ResMed 的持股在最近一個季度末價值 842,000 美元。</p>
<ul>
<li>HCA Healthcare 反彈：減肥藥真的構成重大威脅嗎？</li>
</ul>
<p>其他幾家對沖基金也買賣了 RMD 的股票。Jones Financial Companies Lllp 在第一季度將其在 ResMed 的持股增加了 52.6%。Jones Financial Companies Lllp 目前持有 2,882 股該醫療設備提供商的股票，價值 645,000 美元，此前在上個季度購買了額外的 994 股。Arrowstreet Capital Limited Partnership 在第二季度獲得了 ResMed 的新頭寸，價值 389,000 美元。Brown Advisory Inc. 在第二季度將其在 ResMed 的持股增加了 17.8%。Brown Advisory Inc. 目前持有 1,586 股該醫療設備提供商的股票，價值 409,000 美元，此前在此期間購買了額外的 240 股。Cresset Asset Management LLC 在第二季度獲得了 ResMed 的新頭寸，價值 206,000 美元。最後，Alliancebernstein L.P. 在第二季度將其在 ResMed 的持股增加了 24.2%。Alliancebernstein L.P. 目前持有 286,078 股該醫療設備提供商的股票，價值 73,808,000 美元，此前在此期間購買了額外的 55,790 股。對沖基金和其他機構投資者持有該公司 54.98% 的股票。</p>
<h2>內部人士下注</h2>
<p>在其他 ResMed 的新聞中，董事 Peter C. Farrell 於 4 月 1 日星期三出售了 2,000 股公司的股票。股票以平均價格 225.00 美元出售，總交易額為 450,000.00 美元。該交易在與證券交易委員會的法律文件中披露，可以通過此鏈接訪問。此外，首席執行官 Michael J. Farrell 於 2 月 9 日星期一出售了 4,991 股公司的股票。股票以平均價格 273.78 美元出售，總交易額為 1,366,435.98 美元。交易後，首席執行官持有 466,223 股公司的股票，價值 127,642,532.94 美元。這代表其持股減少了 1.06%。該銷售的披露在 SEC 文件中可用。在過去 90 天內，內部人士已出售價值 4,715,237 美元的 18,973 股公司股票。目前公司內部人士持有 0.65% 的股票。</p>
<h2>分析師設定新目標價</h2>
<p>幾位股票分析師最近對該股票發佈了報告。花旗集團在 4 月 9 日星期四的研究報告中將 ResMed 的目標價格從 345.00 美元下調至 340.00 美元，並對該公司給予了 “買入” 評級。KeyCorp 在 4 月 27 日星期一的研究報告中將 ResMed 的目標價格從 302.00 美元下調至 290.00 美元，並對該公司給予了 “增持” 評級。Evercore 在 4 月 13 日星期一的研究報告中設定了 255.00 美元的目標價格，並給予該公司 “跑贏大盤” 評級。摩根大通在 4 月 15 日星期三的研究報告中開始覆蓋 ResMed 的股票，並對該公司給予了 “增持” 評級。最後，華爾街 Zen 在 3 月 14 日星期六的研究報告中將 ResMed 的評級從 “買入” 下調至 “持有”。一位研究分析師對該股票給予了強烈買入評級，九位分析師給予了買入評級，五位分析師對該股票給予了持有評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價格為 286.18 美元。</p>
<p><strong>查看我們對 ResMed 的最新分析</strong></p>
<h2>ResMed 股票表現</h2>
<p>紐約證券交易所代碼：RMD 週五開盤價為 206.83 美元。該公司的債務與股本比率為 0.06，速動比率為 2.33，流動比率為 3.01。該公司的 50 日移動平均線為 230.41 美元，200 日移動平均線為 245.04 美元。該股票的市值為 301.3 億美元，市盈率為 19.94，市盈增長比率為 1.34，貝塔值為 0.84。ResMed Inc. 的 52 周低點為 198.64 美元，52 周高點為 293.81 美元。</p>
<p>ResMed（紐約證券交易所代碼：RMD - 獲取免費報告）最近於 4 月 30 日星期四發佈了季度財報。該醫療設備提供商報告本季度每股收益為 2.86 美元，超出分析師的共識預期 2.79 美元，超出 0.07 美元。該公司本季度的收入為 14.3 億美元，而分析師的預期為 14.2 億美元。ResMed 的淨利潤率為 27.44%，股本回報率為 25.35%。該公司的季度收入同比增長 10.8%。在去年同期，該公司每股收益為 2.37 美元。整體而言，研究分析師預測 ResMed Inc. 本財年將發佈 11.13 美元的每股收益。</p>
<h2>ResMed 分紅公告</h2>
<p>該公司最近還披露了一項季度分紅，將於 6 月 18 日星期四支付。5 月 14 日星期四的股東將獲得每股 0.60 美元的分紅。除息日為 5 月 14 日星期四。這代表每年 2.40 美元的分紅，收益率為 1.2%。ResMed 的分紅支付比率目前為 23.14%。</p>
<h2>ResMed 公司簡介</h2>
<p>（免費報告）</p>
<p>ResMed NYSE: RMD 是一家全球醫療設備和雲連接公司，專注於改善患有睡眠呼吸障礙和慢性呼吸疾病的人的健康結果。公司成立於 1989 年，總部位於加利福尼亞州聖地亞哥，開發、製造和分銷一系列設備和軟件，供全球的患者、臨牀醫生和提供者使用。</p>
<p>瑞思邁的產品組合以非侵入性通氣和睡眠治療設備為中心，包括持續正壓呼吸器（CPAP）和雙水平設備、面罩及相關配件，用於治療阻塞性睡眠呼吸暫停和其他呼吸系統疾病。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在瑞思邁嗎？</h2>
<p>在考慮瑞思邁之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而瑞思邁並不在名單上。</p>
<p>儘管瑞思邁目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

瑞思邁

標普醫療保健服務 ETF - SPDR

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

<p>Strs Ohio 在第四季度將其在瑞思邁（ResMed Inc.，NYSE:RMD）的持股減少了 89.7%，在出售了 30,494 股後，持有 3,497 股。其他對沖基金也調整了其頭寸，瓊斯金融（Jones Financial）將其持股增加了 52.6%。內部人士在過去 90 天內出售了總計 470 萬美元的股票。分析師們設定了新的價格目標，花旗集團將其目標下調至 340 美元，KeyCorp 則下調至 290 美元。瑞思邁的股票開盤價為 206.83 美元，市值為 301.3 億美元，市盈率為 19.94。該公司報告每股收益為 2.86 美元，超出預期</p>

<p>Strs Ohio trimmed its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 89.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,497 shares of the medical equipment provider's stock after selling 30,494 shares during the period. Strs Ohio's holdings in ResMed were worth $842,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Strs Ohio 在最近向證券交易委員會提交的 13F 文件中表示，在第四季度將其在 ResMed Inc.（紐約證券交易所代碼：RMD - 免費報告）的持股削減了 89.7%。該公司在此期間出售了 30,494 股後，持有 3,497 股該醫療設備提供商的股票。Strs Ohio 在 ResMed 的持股在最近一個季度末價值 842,000 美元。</p>
</div><ul>
<li>HCA Healthcare Rallies: Weight-loss drugs really a big threat?</li>
</ul>
<div class="lb-trans"><ul>
<li>HCA Healthcare 反彈：減肥藥真的構成重大威脅嗎？</li>
</ul>
</div><p>Several other hedge funds have also bought and sold shares of RMD. Jones Financial Companies Lllp increased its holdings in shares of ResMed by 52.6% during the 1st quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider's stock valued at $645,000 after purchasing an additional 994 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of ResMed in the 2nd quarter valued at $389,000. Brown Advisory Inc. lifted its stake in shares of ResMed by 17.8% in the 2nd quarter. Brown Advisory Inc. now owns 1,586 shares of the medical equipment provider's stock valued at $409,000 after purchasing an additional 240 shares during the period. Cresset Asset Management LLC acquired a new position in shares of ResMed in the 2nd quarter valued at $206,000. Finally, Alliancebernstein L.P. lifted its stake in shares of ResMed by 24.2% in the 2nd quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider's stock valued at $73,808,000 after purchasing an additional 55,790 shares during the period. Hedge funds and other institutional investors own 54.98% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金也買賣了 RMD 的股票。Jones Financial Companies Lllp 在第一季度將其在 ResMed 的持股增加了 52.6%。Jones Financial Companies Lllp 目前持有 2,882 股該醫療設備提供商的股票，價值 645,000 美元，此前在上個季度購買了額外的 994 股。Arrowstreet Capital Limited Partnership 在第二季度獲得了 ResMed 的新頭寸，價值 389,000 美元。Brown Advisory Inc. 在第二季度將其在 ResMed 的持股增加了 17.8%。Brown Advisory Inc. 目前持有 1,586 股該醫療設備提供商的股票，價值 409,000 美元，此前在此期間購買了額外的 240 股。Cresset Asset Management LLC 在第二季度獲得了 ResMed 的新頭寸，價值 206,000 美元。最後，Alliancebernstein L.P. 在第二季度將其在 ResMed 的持股增加了 24.2%。Alliancebernstein L.P. 目前持有 286,078 股該醫療設備提供商的股票，價值 73,808,000 美元，此前在此期間購買了額外的 55,790 股。對沖基金和其他機構投資者持有該公司 54.98% 的股票。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total transaction of $450,000.00. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Michael J. Farrell sold 4,991 shares of the company's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $273.78, for a total transaction of $1,366,435.98. Following the transaction, the chief executive officer owned 466,223 shares of the company's stock, valued at $127,642,532.94. This represents a 1.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 18,973 shares of company stock valued at $4,715,237 over the last 90 days. 0.65% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 ResMed 的新聞中，董事 Peter C. Farrell 於 4 月 1 日星期三出售了 2,000 股公司的股票。股票以平均價格 225.00 美元出售，總交易額為 450,000.00 美元。該交易在與證券交易委員會的法律文件中披露，可以通過此鏈接訪問。此外，首席執行官 Michael J. Farrell 於 2 月 9 日星期一出售了 4,991 股公司的股票。股票以平均價格 273.78 美元出售，總交易額為 1,366,435.98 美元。交易後，首席執行官持有 466,223 股公司的股票，價值 127,642,532.94 美元。這代表其持股減少了 1.06%。該銷售的披露在 SEC 文件中可用。在過去 90 天內，內部人士已出售價值 4,715,237 美元的 18,973 股公司股票。目前公司內部人士持有 0.65% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several equities analysts recently issued reports on the stock. Citigroup decreased their target price on shares of ResMed from $345.00 to $340.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, April 9th. KeyCorp decreased their target price on shares of ResMed from $302.00 to $290.00 and set an &#34;overweight&#34; rating for the company in a research note on Monday, April 27th. Evercore set a $255.00 target price on shares of ResMed and gave the company an &#34;outperform&#34; rating in a research note on Monday, April 13th. JPMorgan Chase &amp; Co. assumed coverage on shares of ResMed in a research note on Wednesday, April 15th. They issued an &#34;overweight&#34; rating for the company. Finally, Wall Street Zen cut shares of ResMed from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $286.18.</p>
<div class="lb-trans"><p>幾位股票分析師最近對該股票發佈了報告。花旗集團在 4 月 9 日星期四的研究報告中將 ResMed 的目標價格從 345.00 美元下調至 340.00 美元，並對該公司給予了 “買入” 評級。KeyCorp 在 4 月 27 日星期一的研究報告中將 ResMed 的目標價格從 302.00 美元下調至 290.00 美元，並對該公司給予了 “增持” 評級。Evercore 在 4 月 13 日星期一的研究報告中設定了 255.00 美元的目標價格，並給予該公司 “跑贏大盤” 評級。摩根大通在 4 月 15 日星期三的研究報告中開始覆蓋 ResMed 的股票，並對該公司給予了 “增持” 評級。最後，華爾街 Zen 在 3 月 14 日星期六的研究報告中將 ResMed 的評級從 “買入” 下調至 “持有”。一位研究分析師對該股票給予了強烈買入評級，九位分析師給予了買入評級，五位分析師對該股票給予了持有評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價格為 286.18 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on ResMed</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ResMed 的最新分析</strong></p>
</div><h2>ResMed Stock Performance</h2>
<div class="lb-trans"><h2>ResMed 股票表現</h2>
</div><p>NYSE:RMD opened at $206.83 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. The company has a fifty day moving average of $230.41 and a two-hundred day moving average of $245.04. The stock has a market capitalization of $30.13 billion, a PE ratio of 19.94, a P/E/G ratio of 1.34 and a beta of 0.84. ResMed Inc. has a fifty-two week low of $198.64 and a fifty-two week high of $293.81.</p>
<div class="lb-trans"><p>紐約證券交易所代碼：RMD 週五開盤價為 206.83 美元。該公司的債務與股本比率為 0.06，速動比率為 2.33，流動比率為 3.01。該公司的 50 日移動平均線為 230.41 美元，200 日移動平均線為 245.04 美元。該股票的市值為 301.3 億美元，市盈率為 19.94，市盈增長比率為 1.34，貝塔值為 0.84。ResMed Inc. 的 52 周低點為 198.64 美元，52 周高點為 293.81 美元。</p>
</div><p>ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, topping analysts' consensus estimates of $2.79 by $0.07. The company had revenue of $1.43 billion during the quarter, compared to analysts' expectations of $1.42 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The firm's revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.37 earnings per share. As a group, research analysts forecast that ResMed Inc. will post 11.13 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>ResMed（紐約證券交易所代碼：RMD - 獲取免費報告）最近於 4 月 30 日星期四發佈了季度財報。該醫療設備提供商報告本季度每股收益為 2.86 美元，超出分析師的共識預期 2.79 美元，超出 0.07 美元。該公司本季度的收入為 14.3 億美元，而分析師的預期為 14.2 億美元。ResMed 的淨利潤率為 27.44%，股本回報率為 25.35%。該公司的季度收入同比增長 10.8%。在去年同期，該公司每股收益為 2.37 美元。整體而言，研究分析師預測 ResMed Inc. 本財年將發佈 11.13 美元的每股收益。</p>
</div><h2>ResMed Dividend Announcement</h2>
<div class="lb-trans"><h2>ResMed 分紅公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Shareholders of record on Thursday, May 14th will be given a dividend of $0.60 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a yield of 1.2%. ResMed's dividend payout ratio is currently 23.14%.</p>
<div class="lb-trans"><p>該公司最近還披露了一項季度分紅，將於 6 月 18 日星期四支付。5 月 14 日星期四的股東將獲得每股 0.60 美元的分紅。除息日為 5 月 14 日星期四。這代表每年 2.40 美元的分紅，收益率為 1.2%。ResMed 的分紅支付比率目前為 23.14%。</p>
</div><h2>ResMed Company Profile</h2>
<div class="lb-trans"><h2>ResMed 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.</p>
<div class="lb-trans"><p>ResMed NYSE: RMD 是一家全球醫療設備和雲連接公司，專注於改善患有睡眠呼吸障礙和慢性呼吸疾病的人的健康結果。公司成立於 1989 年，總部位於加利福尼亞州聖地亞哥，開發、製造和分銷一系列設備和軟件，供全球的患者、臨牀醫生和提供者使用。</p>
</div><p>ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.</p>
<div class="lb-trans"><p>瑞思邁的產品組合以非侵入性通氣和睡眠治療設備為中心，包括持續正壓呼吸器（CPAP）和雙水平設備、面罩及相關配件，用於治療阻塞性睡眠呼吸暫停和其他呼吸系統疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than ResMed</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=RMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in ResMed Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在瑞思邁嗎？</h2>
</div><p>Before you consider ResMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮瑞思邁之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而瑞思邁並不在名單上。</p>
</div><p>While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管瑞思邁目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

ResMed Inc. $RMD Shares Sold by Strs Ohio

Market Beat

HCA控股

AllianceBernstein

花旗

科凱國際

Evercore

摩根大通

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

CITIGROUP INC 6.250 NON CUM SER II PFD WI

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

瑞思邁公司 $RMD 的股票被俄亥俄州教師退休系統出售